Published in Circ Res on April 01, 1995
High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. Proc Natl Acad Sci U S A (2008) 1.82
The mechanisms of coronary restenosis: insights from experimental models. Int J Exp Pathol (2000) 1.22
Early growth response factor-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2. Am J Pathol (1999) 1.10
Vascular smooth muscle cell proliferation and regrowth after mechanical injury in vitro are Egr-1/NGFI-A-dependent. Am J Pathol (1999) 1.02
MYB suppresses differentiation and apoptosis of human breast cancer cells. Breast Cancer Res (2010) 0.99
Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint. Proc Natl Acad Sci U S A (1996) 0.89
Positive and negative regulation of c-Myb by cyclin D1, cyclin-dependent kinases, and p27 Kip1. Blood (2005) 0.89
Regulation of cellular proliferation and intimal formation following balloon injury in atherosclerotic rabbit arteries. J Clin Invest (1996) 0.88
Site-specific gene therapy for cardiovascular disease. Curr Opin Drug Discov Devel (2010) 0.87
Sequence-independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynucleotides. J Clin Invest (1996) 0.86
Nemo-like kinase associated with proliferation and apoptosis by c-Myb degradation in breast cancer. PLoS One (2013) 0.82
Smooth muscle-specific expression of calcium-independent phospholipase A2β (iPLA2β) participates in the initiation and early progression of vascular inflammation and neointima formation. J Biol Chem (2012) 0.82
The impact of molecular medicine upon early cardiovascular drug development. Br J Clin Pharmacol (2000) 0.75
Antisense oligonucleotides directed against insulin-like growth factor-II messenger ribonucleic acids delay the progress of rat hepatocarcinogenesis. J Carcinog (2014) 0.75
Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA (2001) 13.93
Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med (1994) 6.78
Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med (1996) 5.94
Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp--specific adhesion receptors. Science (1986) 5.58
Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med (1999) 4.53
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med (1995) 4.29
Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med (2000) 4.19
Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation (1998) 3.92
Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation (1996) 3.82
Association between myeloperoxidase levels and risk of coronary artery disease. JAMA (2001) 3.74
Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem (1979) 3.61
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation (2000) 3.61
Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation (1990) 3.49
Prevention of bioprosthetic heart valve calcification by ethanol preincubation. Efficacy and mechanisms. Circulation (1997) 3.38
Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation (1995) 3.38
Outmigration for coronary bypass surgery in an era of public dissemination of clinical outcomes. Circulation (1996) 3.32
Cultured endothelial cells produce a platelet-derived growth factor-like protein. Proc Natl Acad Sci U S A (1983) 3.29
A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med (1987) 3.04
Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor beta: a proposed model for indirect mitogenesis involving autocrine activity. Proc Natl Acad Sci U S A (1986) 3.04
A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol Cell (2000) 3.03
Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol (2001) 2.99
Use of the flagellar H7 gene as a target in multiplex PCR assays and improved specificity in identification of enterohemorrhagic Escherichia coli strains. J Clin Microbiol (1997) 2.98
Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis (1984) 2.90
Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. N Engl J Med (1996) 2.83
Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa). Cell (1991) 2.81
Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet (1997) 2.80
Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry (1991) 2.66
Failure of sanitary wells to protect against cholera and other diarrhoeas in Bangladesh. Lancet (1976) 2.64
The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci U S A (1985) 2.64
Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif. Trends Biochem Sci (1991) 2.62
Modulation of the affinity of integrin alpha IIb beta 3 (GPIIb-IIIa) by the cytoplasmic domain of alpha IIb. Science (1991) 2.57
Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis (1999) 2.56
Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation (1995) 2.53
The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol (1986) 2.50
Selection of patients with acute myocardial infarction for thrombolytic therapy. Ann Intern Med (1990) 2.48
A beta 3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation. Science (1990) 2.42
Cardiogenic shock complicating acute coronary syndromes. Lancet (2000) 2.42
Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation (1995) 2.38
Cause of death in clinical research: time for a reassessment? J Am Coll Cardiol (1999) 2.36
Monoclonal antibodies to ligand-occupied conformers of integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function. J Biol Chem (1991) 2.34
Specific and saturable binding of plasma fibronectin to thrombin-stimulated human platelets. J Biol Chem (1981) 2.31
Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J (2001) 2.30
Affinity modulation of the alpha IIb beta 3 integrin (platelet GPIIb-IIIa) is an intrinsic property of the receptor. Cell Regul (1990) 2.29
Inside-out integrin signalling. Curr Opin Cell Biol (1992) 2.29
Familial disseminated atypical mycobacterial infection in childhood: a human mycobacterial susceptibility gene? Lancet (1995) 2.29
The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res (1997) 2.28
Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators. Clin Chem (1998) 2.27
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet (2001) 2.23
Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell (1993) 2.22
C-reactive protein: a 'golden marker' for inflammation and coronary artery disease. Cleve Clin J Med (2001) 2.17
Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J Biol Chem (1990) 2.16
Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation (2001) 2.12
Coronary angioplasty volume-outcome relationships for hospitals and cardiologists. JAMA (1997) 2.11
Cost-efficacy modeling of catheter reuse for percutaneous transluminal coronary angioplasty. J Am Coll Cardiol (1996) 2.11
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA (2000) 2.11
Myonecrosis after revascularization procedures. J Am Coll Cardiol (1998) 2.11
Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. Circulation (1998) 2.09
Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation (2001) 2.09
Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA (1999) 2.08
Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation (1995) 2.08
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol (1997) 2.08
Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol (1996) 2.07
Long-term outcome of transient, uncomplicated in-laboratory coronary artery closure. Circulation (1995) 2.06
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. Eur Heart J (2002) 2.06
Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res (1996) 2.05
Mesangial cells express PDGF mRNAs and proliferate in response to PDGF. Am J Physiol (1988) 2.05
Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation. J Biol Chem (1980) 2.05
Refinement of the alpha aminooleic acid bioprosthetic valve anticalcification technique. Ann Thorac Surg (1997) 2.05
Comparison of the ABC/2 estimation technique to computer-assisted volumetric analysis of intraparenchymal and subdural hematomas complicating the GUSTO-1 trial. Stroke (1998) 2.03
One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. Circulation (1996) 2.03
Cytoadhesins, integrins, and platelets. Thromb Haemost (1988) 2.03
The last word on GUSTO, for now. Ann Intern Med (1994) 2.02
Biochemical studies of two patients with the gray platelet syndrome. Selective deficiency of platelet alpha granules. J Clin Invest (1980) 2.01
Practice guidelines and physician scorecards: grading the graders. Cleve Clin J Med (1997) 2.00
Localization of an Arg-Gly-Asp recognition site within an integrin adhesion receptor. Science (1988) 1.98
Platelet GPIIb-IIIa blockers. Lancet (1999) 1.97
Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets. Blood (1985) 1.95
Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes. J Med Genet (2004) 1.94
Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med (1995) 1.93
A potential basis for the thrombotic risks associated with lipoprotein(a). Nature (1989) 1.93
Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol (1996) 1.91
Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J (1990) 1.90
Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation (1996) 1.87
Evidence that three adhesive proteins interact with a common recognition site on activated platelets. J Biol Chem (1984) 1.83
Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation (2001) 1.83
Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. Circulation (1990) 1.83
Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol (1992) 1.82